Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.
Tamai
H
H
Shioi
Y
Y
Yamaguchi
H
H
Okabe
M
M
Wakita
S
S
Mizuki
T
T
Nakayama
K
K
Inokuchi
K
K
Tajika
K
K
Dan
K
K
D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D005260:Female; D000079982:Gemtuzumab; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000922:Immunotoxins; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy*; D017710:Lymphocyte Transfusion; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D013997:Time Factors; D014019:Tissue Donors; D014178:Translocation, Genetic; D014184:Transplantation, Homologous
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000922:Immunotoxins; C447400:MLL-AF6 fusion protein, human; D015514:Oncogene Proteins, Fusion; D051788:Myeloid-Lymphoid Leukemia Protein; D000079982:Gemtuzumab